Position in CRBU
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$60,649
-$4,825 QoQ
Shares Held
34,460
0.0% QoQ
Ownership
0.032%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#68
of 137 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CRBU Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026HSBC HOLDINGS PLC holds $1,221,504,678 across 135 Biotechnology names. CRBU ranks #122 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
676,247 | $335,912,169 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
382,028 | $238,209,735 | |
| 3 | INCY |
Incyte Corp
|
1,307,743 | $148,245,744 | |
| 4 | RPRX |
Royalty Pharma plc
|
1,224,925 | $68,681,542 | |
| 5 | MRNA |
Moderna, Inc.
|
636,199 | $44,553,014 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
115,279 | $34,702,435 | |
| 7 | INSM |
INSMED Inc
|
279,961 | $29,849,438 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
307,543 | $17,597,610 |
All Filings in CRBU
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $60,649 | 34,460 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $65,474 | 34,460 | Shares | Defined | 2026-04-30 | |
| 2025-12-31 | $54,791 | 34,460 | Shares | Defined | 2026-03-06 | |
| 2025-09-30 | $80,291 | 34,460 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $144,450 | 114,643 | Shares | Defined | 2025-08-13 | |
| 2025-03-31 | $43,799 | 47,973 | Shares | Defined | 2025-05-14 | |
| 2024-12-31 | $76,377 | 48,036 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $88,543 | 45,175 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $132,621 | 80,867 | Shares | Defined | 2024-08-12 | |
| 2024-03-31 | $72,109 | 14,029 | Shares | Defined | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||